Avanir Pharmaceuticals, Inc.
http://www.avanir.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avanir Pharmaceuticals, Inc.
Third Rock Thinks Its Model Reassures Investors In Difficult Times
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.
Kriya Raises $270m To Scale Gene Therapy Platform, Move Into The Clinic
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
Keeping Track: Mycovia Vivjoa, BMS Camzyos Approvals Bring FDA’s 2022 Novel Drug Tally To 12
US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
Company Information
- Other Names / Subsidiaries
-
- Alamo Pharmaceuticals, LLC